Fintel reports that on December 12, 2024, Guggenheim downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Buy to Neutral. Analyst Price Forecast Suggests 1,981.80% Upside As of December 3, 2024, ...

Q32 Bio Inc (QTTB) stock saw a decline, ending the day at $5.95 which represents a decrease of $-18.46 or -75.62% from the prior close of $24.41. The stock opened at $8 and touched a low of $5.8 ...

Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.

BMO Capital lowered the firm’s price target on Q32 Bio (QTTB) to $22 from $64 but keeps an Outperform rating on the shares. The company ...

As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the ...

US clinical-stage biotech Q32 Bio (Nasdaq: QTTB) saw its shares plunge 75.6% to $5.59 yesterday, after providing a mixed ...

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming apart due to an error in patient ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.